Inner Mongolia Furui Medical Science Co Ltd
SZSE:300049
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
27.48
87.87
|
| Price Target |
|
We'll email you a reminder when the closing price reaches CNY.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| CN |
I
|
Inner Mongolia Furui Medical Science Co Ltd
SZSE:300049
|
18.1B CNY |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
969.6B USD |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.3B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
277.1B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
209.4B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
219B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
271.3B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
148.3B USD |
Loading...
|
|
| FR |
|
Sanofi SA
PAR:SAN
|
93.8B EUR |
Loading...
|
Market Distribution
| Min | -409 046.1% |
| 30th Percentile | -1.4% |
| Median | 4.2% |
| 70th Percentile | 10.3% |
| Max | 876.4% |
Other Profitability Ratios
Inner Mongolia Furui Medical Science Co Ltd
Glance View
In the vast expanse of the healthcare landscape, Inner Mongolia Furui Medical Science Co., Ltd. has carved its niche by melding traditional Chinese medical wisdom with contemporary scientific advancements. Founded in the milieu of China's rich cultural heritage in Inner Mongolia, the company has emerged as a pivotal player in the pharmaceutical and biotechnology sectors. It specializes in the research, development, production, and sale of heparin products. Heparin, an anticoagulant drug crucial in preventing and treating blood clots, has been the cornerstone of Furui Medical's success, establishing them as a key supplier in both domestic and international markets. By leveraging China's comprehensive supply chain and stringent quality control measures, Furui has ensured its products meet the demanding standards of healthcare providers worldwide. At the heart of Furui Medical's business model is a well-oiled system that not only focuses on enhancing product efficacy but also strives for innovation in its production processes. The company has invested significantly in building state-of-the-art manufacturing facilities and a robust R&D department, which allow it to maintain a competitive edge in the biopharmaceutical domain. This focus on technological enhancement and adherence to international quality standards facilitates Furui Medical's penetration into global markets, particularly in Europe and North America. Additionally, their strategic partnerships and expansive distribution networks help them capitalize on emerging opportunities in the global anticoagulant market. Through this blend of tradition and modernity, Furui Medical not only contributes to the healing arts but also ensures sustainable business growth.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Inner Mongolia Furui Medical Science Co Ltd is 22.2%, which is above its 3-year median of 21.1%.
Over the last 3 years, Inner Mongolia Furui Medical Science Co Ltd’s Operating Margin has increased from 16.8% to 22.2%. During this period, it reached a low of 16.8% on Sep 30, 2022 and a high of 24.1% on Mar 31, 2024.